Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.
about
Current and emerging treatment options for patients with relapsed myelomaLenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-AnalysisCurrent therapy of myelodysplastic syndromesUpdate on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Clinical utility of lenalidomide in the treatment of myelodysplastic syndromesLenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatmentEffect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletionSubsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesChoosing treatment options for patients with relapsed/refractory multiple myeloma.Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited.In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.Guidelines for the diagnosis and management of adult myelodysplastic syndromes.
P2860
Q26830878-913EB291-E5CA-46DE-AECA-F732F2709C10Q33408873-735BAA6C-B627-4DB8-A71B-84EBE3C6A240Q33424228-5F066E35-EC54-4E5E-B501-91A9052E9823Q33436627-EA9668EA-D61D-4DDE-AA6A-C4ADD45394A1Q34013796-E7512D11-D7D7-4C23-AE35-D2E4835CCA6AQ34253548-8B40FE3C-FDB3-46A8-B573-1BAAB05B833EQ34783754-8A593433-536D-4BD0-92DA-0C55F710814CQ36832931-4FAFC9BB-972F-4B2B-B92F-C70FC4388476Q37001825-64BA0B55-484B-4DF7-9389-EA3F65F6A15EQ37075929-9FB1292F-105E-4737-B8AC-476E7CF7E5CDQ37094962-5DC5E2E7-425A-47AA-B836-F0812F5EB20AQ37441528-F8BD1584-A948-40A6-9083-206EB5133DEBQ38135713-0264C533-C5A1-4D15-B138-265E6CD1F5A1Q38170453-62B810A0-5258-4DDE-9FE9-309033874473Q39576312-D01FF611-EBE7-4270-9E09-1FAC3662A59AQ41748682-E6E52F84-7B76-4DE4-8732-0EC490860FFAQ44375454-F25821A5-4595-4EE6-BA90-951D303E34F1Q54392826-BD459B11-2251-4547-A5E5-C1D155E617A8
P2860
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Treatment with lenalidomide do ...... ancophone des Myelodysplasies.
@ast
Treatment with lenalidomide do ...... ancophone des Myelodysplasies.
@en
type
label
Treatment with lenalidomide do ...... ancophone des Myelodysplasies.
@ast
Treatment with lenalidomide do ...... ancophone des Myelodysplasies.
@en
prefLabel
Treatment with lenalidomide do ...... ancophone des Myelodysplasies.
@ast
Treatment with lenalidomide do ...... ancophone des Myelodysplasies.
@en
P2093
P2860
P50
P1433
P1476
Treatment with lenalidomide do ...... ancophone des Myelodysplasies.
@en
P2093
Agnès Guerci Bresler
Alain Delmer
Anne Banos
Charikleia Kelaidi
Eric Wattel
Fabien Le Bras
François Dreyfus
Jacques Delaunay
Lionel Adès
Marie Sebert
P2860
P304
P356
10.3324/HAEMATOL.2011.045914
P577
2011-10-11T00:00:00Z